JP2009544281A5 - - Google Patents

Info

Publication number

JP2009544281A5

JP2009544281A5 JP2009519879A JP2009519879A JP2009544281A5 JP 2009544281 A5 JP2009544281 A5 JP 2009544281A5 JP 2009519879 A JP2009519879 A JP 2009519879A JP 2009519879 A JP2009519879 A JP 2009519879A JP 2009544281 A5 JP2009544281 A5 JP 2009544281A5

Authority

JP

Japan

Prior art keywords

seq

stretch

set forth

sequence set

nucleotide sequence

Prior art date

2007-07-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003729 nucleotide group Chemical group 0.000 claims 77
• 239000002773 nucleotide Substances 0.000 claims 72
• 150000007523 nucleic acids Chemical class 0.000 claims 28
• 108020004707 nucleic acids Proteins 0.000 claims 26
• 102000039446 nucleic acids Human genes 0.000 claims 26
• 230000000295 complement effect Effects 0.000 claims 8
• 239000002479 lipoplex Substances 0.000 claims 5
• 239000002502 liposome Substances 0.000 claims 5
• 239000000203 mixture Substances 0.000 claims 5
• 230000004048 modification Effects 0.000 claims 3
• 238000012986 modification Methods 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 238000002360 preparation method Methods 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
• 230000033115 angiogenesis Effects 0.000 claims 2
• 230000001419 dependent effect Effects 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• BKHMAOXOKNEKHL-NNJYRKLXSA-N (5s)-2,3,5-triamino-8-(diaminomethylideneamino)-n-hexadecyl-n-[(z)-octadec-9-enyl]-4-oxooctanamide;trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCCCN(C(=O)C(N)C(N)C(=O)[C@@H](N)CCCNC(N)=N)CCCCCCCC\C=C/CCCCCCCC BKHMAOXOKNEKHL-NNJYRKLXSA-N 0.000 claims 1
• XLPHMKQBBCKEFO-DHYROEPTSA-N 2-azaniumylethyl [(2r)-2,3-bis(3,7,11,15-tetramethylhexadecanoyloxy)propyl] phosphate Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C XLPHMKQBBCKEFO-DHYROEPTSA-N 0.000 claims 1
• 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
• 102000004895 Lipoproteins Human genes 0.000 claims 1
• 108090001030 Lipoproteins Proteins 0.000 claims 1
• 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims 1
• 239000002202 Polyethylene glycol Substances 0.000 claims 1
• 238000002296 dynamic light scattering Methods 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 229940071238 n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Drugs 0.000 claims 1
• 229940113162 oleylamide Drugs 0.000 claims 1
• 229920001223 polyethylene glycol Polymers 0.000 claims 1
• 159000000000 sodium salts Chemical class 0.000 claims 1
• 239000003981 vehicle Substances 0.000 claims 1